Bruker Corporation (BRKR) Given Consensus Rating of “Hold” by Analysts
Bruker Corporation (NASDAQ:BRKR) has received a consensus recommendation of “Hold” from the fifteen research firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $26.70.
Several research firms have recently issued reports on BRKR. Wells Fargo & Company cut Bruker Corporation from a “market perform” rating to an “underperform” rating in a research report on Wednesday, July 12th. Zacks Investment Research raised Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research report on Thursday, July 6th. BidaskClub cut Bruker Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Barclays PLC reaffirmed an “equal weight” rating and set a $30.00 price objective (up from $26.00) on shares of Bruker Corporation in a research report on Monday, July 17th. Finally, Cowen and Company reaffirmed a “hold” rating and set a $29.00 price objective on shares of Bruker Corporation in a research report on Friday, July 14th.
ILLEGAL ACTIVITY NOTICE: “Bruker Corporation (BRKR) Given Consensus Rating of “Hold” by Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/11/bruker-corporation-brkr-given-consensus-rating-of-hold-by-analysts.html.
Shares of Bruker Corporation (NASDAQ BRKR) traded up 1.66% during midday trading on Wednesday, hitting $30.61. The company had a trading volume of 295,649 shares. The company has a 50-day moving average of $29.53 and a 200 day moving average of $27.29. Bruker Corporation has a 12 month low of $19.58 and a 12 month high of $30.74. The firm has a market capitalization of $4.86 billion, a PE ratio of 30.52 and a beta of 1.09.
Bruker Corporation (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.03. The business had revenue of $414.90 million during the quarter, compared to analysts’ expectations of $384.75 million. Bruker Corporation had a return on equity of 26.66% and a net margin of 9.65%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.20 EPS. On average, analysts expect that Bruker Corporation will post $1.12 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 22nd. Shareholders of record on Tuesday, September 5th were paid a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend was Thursday, August 31st. Bruker Corporation’s dividend payout ratio is presently 16.00%.
In related news, CEO Frank H. Laukien acquired 2,335 shares of Bruker Corporation stock in a transaction on Thursday, August 10th. The stock was purchased at an average cost of $27.39 per share, with a total value of $63,955.65. Following the purchase, the chief executive officer now directly owns 37,791,386 shares in the company, valued at $1,035,106,062.54. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Mark Munch sold 21,061 shares of the company’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the sale, the vice president now directly owns 60,524 shares of the company’s stock, valued at $1,813,904.28. The disclosure for this sale can be found here. 35.20% of the stock is owned by corporate insiders.
Several hedge funds have recently modified their holdings of the company. Alps Advisors Inc. raised its stake in shares of Bruker Corporation by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 20,154 shares of the medical research company’s stock worth $581,000 after buying an additional 52 shares in the last quarter. Utah Retirement Systems raised its stake in shares of Bruker Corporation by 1.1% during the 2nd quarter. Utah Retirement Systems now owns 19,189 shares of the medical research company’s stock worth $553,000 after buying an additional 200 shares in the last quarter. Federated Investors Inc. PA raised its stake in shares of Bruker Corporation by 0.3% during the 2nd quarter. Federated Investors Inc. PA now owns 60,553 shares of the medical research company’s stock worth $1,746,000 after buying an additional 204 shares in the last quarter. Tudor Investment Corp ET AL raised its stake in shares of Bruker Corporation by 1.5% during the 2nd quarter. Tudor Investment Corp ET AL now owns 15,980 shares of the medical research company’s stock worth $461,000 after buying an additional 242 shares in the last quarter. Finally, Public Employees Retirement System of Ohio raised its stake in shares of Bruker Corporation by 0.7% during the 1st quarter. Public Employees Retirement System of Ohio now owns 48,267 shares of the medical research company’s stock worth $1,126,000 after buying an additional 312 shares in the last quarter. 65.42% of the stock is owned by institutional investors and hedge funds.
Bruker Corporation Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.